CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Supernus, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Supernus, Inc.
9715 Key West Avenue
Phone: (804) 379-1090p:804 379-1090 ROCKVILLE, MD  20850  United States Ticker: SUPNSUPN
Business Summary
Supernus, Inc., formerly Indivior Pharmaceuticals, Inc., is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The Company's commercial platform offers various product portfolios consisting of opioid use disorder, psychiatry, and neurology, and includes five core growth drivers, including SUBLOCADE, Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE. Its portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202612/31/2025YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
6719 Offices of holding companies, not elsewhere classified
8741 Management services
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board TonyKingsley 62 11/2/2026 7/1/2025
Chief Executive Officer, Director Jack A.Khattar 65 11/2/2026 11/2/2026
Senior Vice President, Chief Financial Officer Timothy C.Dec 68 11/2/2026 11/2/2026
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Indivior Finance S.ar.l. Luxembourg
RBP Global Holdings, Ltd. 103-105 Bath Road Berkshire United Kingdom
Sage Therapeutics GmbH c/o Cormoran GmbH Am Zirkus 2 Berlin Germany
9 additional Subsidiary records available in full report.

Business Names
Business Name
A12FHW
Adamas Pharmaceuticals Inc
Bio-Found Limited
74 additional Business Names available in full report.

General Information
Number of Employees: 827 (As of 12/31/2025)
Outstanding Shares: 207,724,098 (As of 11/2/2026)
Shareholders: 139
Stock Exchange: NASD
Federal Tax Id: 412520873


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 14, 2026